Senti Biosciences, Inc., also known as SNTI, is a pioneering biotechnology company located in South San Francisco, California. Known for its innovative work in synthetic biology, the company's principal focus is on designing gene circuits to transform cells into therapeutic devices that can be programmed to treat more diseases in more people.
Senti Biosciences' proprietary technology is based on creating smart, tunable, and versatile cell and gene therapies. These therapies can understand the sophisticated parameters of human diseases better and can respond to these conditions in a precise and potent manner. The Senti platform takes standard cell therapy and gives it a 'control system' – enabling cell therapies to 'understand' the signals within the body, 'make decisions,' and 'execute' sophisticated actions towards treating the root cause of the disease.
In less than a half-decade since being incorporated, Senti Biosciences has emerged as a transformational player in the gene and cell therapy space. It is backed by leading investors in life sciences including NEA, 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital.
Recognizing the potential of the company's technological advancements, the Business Insider named Senti Biosciences as one of the 11 biotech startups promising to "revolutionize healthcare" in 2020. One of the factors in this recognition was the company's development of an adaptive T cell therapy for cancer that uses its gene circuit platform. This therapy makes it possible to develop clinical applications for a variety of diseases.
While the company's research and development are primarily focused on oncology, it is also expanding its efforts into immunology, neuroscience, cardiology, and genetic diseases. Senti Biosciences envisions a future where biology will become the next computation platform and aims to use its technologies to create the next generation of cell and gene therapies targeting many severely damaging diseases with limited or no treatment available.
The focus on improving humanity's quality of life is resolute at Senti Biosciences, as seen from their motto, “humanity at our core, engineering in our DNA, and humility in our hearts”. The company's exponential growth and advancements in the biotech field continue to inspire optimism not just in the investors but also patients and medical practitioners worldwide.